A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice

Lee, Byoung-Hee; Yoshimatsu, Kumiko; Araki, Koichi; Okumura, Megumi J.; Nakamura, Ichiro; Arikawa, Jiro

doi:10.1016/j.vaccine.2005.12.040

Cited by 29 publications

(18 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most of the experiments reported here, we measured the neutralizing antibody response to the vaccines using two methods: the PsVNA and the classic PRNT. The PRNT measures hantavirus neutralizing antibodies against authentic hantavirus performed in BSL-3 containment, whereas the hantavirus PsVNA involves defective VSV expressing a luciferase reporter pseudotyped with the hantavirus glycoproteins [18, 19, 31]. These assays can be performed rapidly and do not require containment.…”

Section: Discussionmentioning

confidence: 99%

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Kwilas¹,

Kishimori²,

Josleyn³

et al. 2014

CGT

View full text Add to dashboard Cite

Sin Nombre virus (SNV) and Andes virus (ANDV) cause most of the hantavirus pulmonary syndrome (HPS) cases in North and South America, respectively. The chances of a patient surviving HPS are only two in three. Previously, we demonstrated that SNV and ANDV DNA vaccines encoding the virus envelope glycoproteins elicit high-titer neutralizing antibodies in laboratory animals, and (for ANDV) in nonhuman primates (NHPs). In those studies, the vaccines were delivered by gene gun or muscle electroporation. Here, we tested whether a combined SNV/ANDV DNA vaccine (HPS DNA vaccine) could be delivered effectively using a disposable syringe jet injection (DSJI) system (PharmaJet, Inc). PharmaJet intramuscular (IM) and intradermal (ID) needle-free devices are FDA 510(k)-cleared, simple to use, and do not require electricity or pressurized gas. First, we tested the SNV DNA vaccine delivered by PharmaJet IM or ID devices in rabbits and NHPs. Both IM and ID devices produced high-titer anti-SNV neutralizing antibody responses in rabbits and NHPs. However, the ID device required at least two vaccinations in NHP to detect neutralizing antibodies in most animals, whereas all animals vaccinated once with the IM device seroconverted. Because the IM device was more effective in NHP, the Stratis® (PharmaJet IM device) was selected for follow-up studies. We evaluated the HPS DNA vaccine delivered using Stratis® and found that it produced high-titer anti-SNV and anti-ANDV neutralizing antibodies in rabbits (n=8/group) as measured by a classic plaque reduction neutralization test and a new pseudovirion neutralization assay. We were interested in determining if the differences between DSJI delivery (e.g., high-velocity liquid penetration through tissue) and other methods of vaccine injection, such as needle/syringe, might result in a more immunogenic DNA vaccine. To accomplish this, we compared the HPS DNA vaccine delivered by DSJI versus needle/syringe in NHPs (n=8/group). We found that both the anti-SNV and anti-ANDV neutralizing antibody titers were significantly higher (p-value 0.0115) in the DSJI-vaccinated groups than the needle/syringe group. For example, the anti-SNV and anti-ANDV PRNT50 geometric mean titers (GMTs) were 1,974 and 349 in the DSJI-vaccinated group versus 87 and 42 in the needle/syringe group. These data demonstrate, for the first time, that a spring-powered DSJI device is capable of effectively delivering a DNA vaccine to NHPs. Whether this HPS DNA vaccine, or any DNA vaccine, delivered by spring-powered DSJI will elicit a strong immune response in humans, requires clinical trials.

show abstract

Section: Discussionmentioning

confidence: 99%

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Kwilas¹,

Kishimori²,

Josleyn³

et al. 2014

CGT

View full text Add to dashboard Cite

show abstract

“…The hantavirus glycoproteins are typically thought to be the principal targets of neutralizing antibodies (1,8,39,51), and although a few potential vaccine candidates have been evaluated with various degrees of success, largely in infection rather than disease models (2,7,10,21,24,25,35,56,60,72,73), the mechanism of protection against hantavirus infections remain unidentified. Here we constructed an attenuated, replication-competent recombinant VSV expressing the ANDV GPC in order to investigate its efficacy as a hantavirus vaccine in the Syrian hamster HPS disease model and to gain further insight into the mechanism of protection against lethal ANDV infection.…”

Section: Discussionmentioning

confidence: 99%

“…1) represents a unique attenuated replication-competent VSV construct that expresses a glycoprotein from a bunyavirus, although replication-incompetent VSV particles have previously been pseudotyped with glycoproteins from "Old World" (35,49) and "New World" (54,60) hantaviruses. Bunyaviruses are generally believed to mature and bud from the Golgi apparatus, including the incorporation of the glycoproteins into virus particles (63).…”

Section: Discussionmentioning

confidence: 99%

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Brown

Safronetz

Marzi

et al. 2011

J Virol

View full text Add to dashboard Cite

Andes virus (ANDV) is a highly pathogenic South American hantavirus that causes hantavirus pulmonary syndrome (HPS).A high case fatality rate, the potential for human-to-human transmission, the capacity to infect via aerosolization, and the absence of effective therapies make it imperative that a safe, fast-acting, and effective ANDV vaccine be developed. We generated and characterized a recombinant vesicular stomatitis virus (VSV) vector expressing the ANDV surface glycoprotein precursor (VSV⌬G/ANDVGPC) as a possible vaccine candidate and tested its efficacy in the only lethal-disease animal model of HPS. Syrian hamsters immunized with a single injection of VSV⌬G/ANDVGPC were fully protected against disease when challenged at 28, 14, 7, or 3 days postimmunization with a lethal dose of ANDV; however, the mechanism of protection seems to differ depending on when the immunization occurs. At 28 days postimmunization, a lack of detectable ANDV RNA in lung, liver, and blood tissue samples, as well as a lack of seroconversion to the ANDV nucleocapsidprotein in nearly all animals, suggested largely sterile immunity. The vaccine was able to generate high levels of neutralizing anti-ANDV G N /G C antibodies, which seem to play a role as a mechanism of vaccine protection. Administration of the vaccine at 7 or 3 days before challenge also resulted in full protection but with no specific neutralizing humoral immune response, suggesting a possible role of innate responses in protection against challenge virus replication. Administration of the vaccine 24 h postchallenge was successful in protecting 90% of hamsters and again suggested the induction of a potent antiviral state by the recombinant vector as a potential mechanism. Overall, our data suggest the potential for the use of the VSV platform as a fast-acting and effective prophylaxis/postexposure treatment against lethal hantavirus infections.

show abstract

“…A vaccinia virusvectored vaccine containing the M and S genes of HTNV was found to elicit neutralizing antibodies in humans; however, preexisting immunity to vaccinia (smallpox vaccination) lessened its efficacy (McClain et al, 2000). In another approach, HTNV glycoprotein genes were used to pseudotype vesicular stomatitis virus (Lee et al, 2006). This vaccine elicited neutralizing antibodies in mice and protected against HTNV infection.…”

Section: Vaccinesmentioning

confidence: 99%

Treatment of hantavirus pulmonary syndrome

2008

View full text Add to dashboard Cite

Viruses in the genus Hantavirus can cause one of two serious illnesses when transmitted from rodents to humans: hemorrhagic fever with renal syndrome (HFRS) or hantavirus pulmonary syndrome (HPS). Of the two diseases, HPS is more severe with an approximate 40% mortality across the Americas. The high rate of mortality could be reduced if effective therapeutics could be discovered for treatment of this illness. Herein we review approaches being explored for the discovery of therapeutics for HPS and how they could be employed in treatment and prevention of disease.

show abstract

A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice

Cited by 29 publications

References 29 publications

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

A Hantavirus Pulmonary Syndrome (HPS) DNA Vaccine Delivered Using a Spring-powered Jet Injector Elicits a Potent Neutralizing Antibody Response in Rabbits and Nonhuman Primates

Vesicular Stomatitis Virus-Based Vaccine Protects Hamsters against Lethal Challenge with Andes Virus

Treatment of hantavirus pulmonary syndrome

Contact Info

Product

Resources

About